The Indian Journal of Pediatrics

, Volume 77, Issue 9, pp 969–973 | Cite as

Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience

  • Gurjit Kaur
  • Jyoti Srivastav
  • Suksham Jain
  • Deepak Chawla
  • Bir S. Chavan
  • Rajiv Atwal
  • Gurpreet Randhawa
  • Avneet Kaur
  • Rajendra Prasad



To establish newborn screening in Indian scenario that could lay a framework for future such initiatives. Three disorders namely, congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH) and glucose-6-phosphate dehydrogenase deficiency (G-6-PDD) were selected for a preliminary study for newborn screening.


Heel-prick blood samples were collected from live-born neonates at 24–48 h of birth as a part of a screening program after prior written consent from the parents. Blood levels of glucose-6-phosphate-dehydrogenase enzyme (G-6-PD), thyroid-stimulating hormone (TSH) and 17-α-OH progesterone (17-OHP) were measured using DELFIA time resolved fluoroimmunoassay.


Six thousand eight hundred and thirteen (6,813) neonates (86.3%), out of a total of 7,893 live births in our institute during the period May’2007 through July’2009, were screened for CAH, CH and G6PD deficiency. Major reason for missing samples was early discharge of the neonates and admission to the neonatal intensive care unit. G-6-PD deficiency was confirmed in 61 cases, congenital hypothyroidism (CH) in 2 cases and congenital adrenal hyperplasia (CAH) in 1 neonate, accounting for an incidence of 1/112 for G-6-PDD, 1/ 3400 for CH and 1/6813 for CAH.


Preliminary data on prevalence of various genetic disorders viz. G-6-PDD, CH and CAH in the population of this region revealed that G-6-PDD is most prevalent disorder followed by CH and CAH. More efforts need to be undertaken to create awareness and emphasis on significance of preventive testing to make screening a successful program in India.


Neonatal screening in India Neonatal screening Genetic disorders in India 



The authors would like to acknowledge the complete financial assistance extended by Chandigarh Administration for this study. All neonates were screened free of cost.


Kaur G: Design and plan of the study.

Srivastav J: Data Analysis, Calculation of prevalence and Preparation of manuscript.

Jain S: Neonatologist responsible for follow-up and management of high risk neonates.

Chawla D: Neonatologist responsible for follow-up and management of high risk neonates.

Chavan B.S: Design and plan of the study

Atwal R: Biochemical analysis of 17α-OH Progesterone, neonatal TSH and G6PD.

Randhawa G: Pre-test counseling to all parents signifying the importance of screening and consent taking in prescribed Performa.

Kaur A: Pre test counseling to all parents signifying the importance of screening and consent taking in prescribed Performa.

Prasad R: Evaluation of data and preparation of final manuscript.

Conflict of interest


Role of funding source

To establish neonatal screening program in a government organization to identify metabolic disorders in asymptomatic phase and prevent associated physical and mental handicap.


  1. 1.
    Choudhuri T, Sengupta S. Inborn errors of metabolism—an Indian perspective. Int J Hum Genet. 2006;6:89–91.Google Scholar
  2. 2.
    ICMR. Collaborating centers and Central coordinating unit. Multicentric study on genetic causes of mental retardation in India. Indian J Med Res. 1991;94:161–9.Google Scholar
  3. 3.
    Verma IC, Bijarnia S. The burden of genetic disorders in India and a framework for community control. Community Genet. 2002;5:192–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Dutta R. ICMR to conduct first nationwide newborn screening for genetic disorders. Express HealthCare Management. 1st–15th September 2005.Google Scholar
  5. 5.
    Scriver CR, Beaudet AL, Valle D, Sly WS. The metabolic and molecular basis of inherited disease. 6th ed. New York: McGraw-Hill; 1989;1165–80.Google Scholar
  6. 6.
    Ramadevi AR, Naushad SM. Newborn screening in India. Indian J Pediatr. 2004;71:157–60.CrossRefGoogle Scholar
  7. 7.
    Ramadevi AR, Rao A. Neonatal screening in India. ICMR Report 1989.Google Scholar
  8. 8.
    Bhasin MK. Genetics of castes and tribes of India: glucose-6-phosphate dehydrogenase deficiency and abnormal haemoglobins (HbS and HbE). Int J Hum Genet. 2006;6:49–72.Google Scholar
  9. 9.
    Olgemoller B, Roscher AA, Liebel B, Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab. 2003;88:5790–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968;26–7.Google Scholar
  11. 11.
    The Changing Moral Focus of Newborn Screening. An ethical analysis by the President’s Council on bioethics. 2008. Washington, DC.
  12. 12.
    Committee on Genetics. Issues in newborn screening. Pediatrics. 1992;89:345–9.Google Scholar
  13. 13.
    Neonatal Guidelines 9. Newborn screening. British Columbia Reproductive Care Program, November, 1999; 1–5.Google Scholar
  14. 14.
    Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006;117:2290–303.CrossRefPubMedGoogle Scholar
  15. 15.
    Newborn Screening Practitioner’s Manual. The Mountain States Genetics Network. 2003
  16. 16.
    Toublanc JE. Guidelines for neonatal screening programs for congenital hypothyroidism. Acta Paediatr Suppl. 1999;432:13–4.CrossRefGoogle Scholar
  17. 17.
    Amar HSS. Screening for congenital hypothyroidism in Southeast Asia. J Paediatr Obstet Gynaecol. 1997;1:5–9.Google Scholar
  18. 18.
    Kaye CI, Committee on Genetics. Introduction to the newborn screening fact sheets. Pediatrics. 2006;118:1304–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Low LCK, Lin HJ, Cheung PT, Lee FT, Chu SY, Kwok TL, et al. Screening for congenital hypothyroidism in Hong Kong. Aust Paediatr J. 1986;22:53–6.PubMedGoogle Scholar
  20. 20.
    American Academy of Pediatrics. Newborn screening for congenital hypothyroidism: recommended guidelines. Pediatrics. 1993;91:1203–9.Google Scholar
  21. 21.
    Lott JA, Sardovia-Iyer M, Lee KK. Age-dependent cutoff values in screening newborns for hypothyroidism. Clin Biochem. 2004;37:791–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Lafranchi S. Hypothyroidism. In: Behrman RE, Kleigman RM, Jenson HB, editors. Nelson textbook of pediatrics. 17th ed. Philadelphia: Saunders; 2004;1872–9.Google Scholar
  23. 23.
    Tripathy V, Reddy BM. Present status of understanding on the G6PD deficiency and natural selection. J Postgrad Med. 2007;53:193–202.CrossRefPubMedGoogle Scholar
  24. 24.
    Newborn Blood-Spot Screening. HGSA-RACP Newborn Screening Joint Subcommittee. HGSA Policy Statement 2004.
  25. 25.
    Wilcken B, Wiley V. Newborn screening. Pathology. 2008;40:104–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis. 2007;30:490–506.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2010

Authors and Affiliations

  • Gurjit Kaur
    • 1
  • Jyoti Srivastav
    • 1
  • Suksham Jain
    • 2
  • Deepak Chawla
    • 2
  • Bir S. Chavan
    • 1
  • Rajiv Atwal
    • 1
  • Gurpreet Randhawa
    • 1
  • Avneet Kaur
    • 1
  • Rajendra Prasad
    • 3
  1. 1.Genetic CentreGovernment Medical College & HospitalChandigarhIndia
  2. 2.Department of PediatricsGovernment Medical College & HospitalChandigarhIndia
  3. 3.Department of BiochemistryPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations